DAEWON PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14,810 KRW | -0.87% |
|
-2.57% | -5.43% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 335,002 | 380,715 | 342,999 | 393,197 | 331,930 | 313,914 | - | - |
| Enterprise Value (EV) 2 | 366.2 | 380.7 | 343 | 465.9 | 331.9 | 356.6 | 332.6 | 313.9 |
| P/E ratio | 11.9 x | - | 47.7 x | 12.7 x | 14.1 x | 9.62 x | 7.91 x | 6.76 x |
| Yield | 1.55% | - | 1.24% | 1.07% | - | 2.03% | 2.25% | 2.03% |
| Capitalization / Revenue | 1.05 x | 1.23 x | 0.97 x | 0.82 x | 0.63 x | 0.5 x | 0.5 x | 0.43 x |
| EV / Revenue | 1.15 x | 1.23 x | 0.97 x | 0.97 x | 0.63 x | 0.57 x | 0.53 x | 0.43 x |
| EV / EBITDA | 8.28 x | - | 9.21 x | 7.47 x | 6.67 x | 5.24 x | 4.69 x | 3.92 x |
| EV / FCF | 46.9 x | - | - | 18.4 x | - | 10.8 x | 6.28 x | 5.51 x |
| FCF Yield | 2.13% | - | - | 5.43% | - | 9.25% | 15.9% | 18.2% |
| Price to Book | 1.61 x | - | 1.52 x | 1.57 x | - | 1.18 x | 1.05 x | 0.88 x |
| Nbr of stocks (in thousands) | 21,571 | 21,224 | 21,219 | 20,971 | 21,196 | 21,196 | - | - |
| Reference price 3 | 15,530 | 17,938 | 16,165 | 18,750 | 15,660 | 14,810 | 14,810 | 14,810 |
| Announcement Date | 3/12/20 | 2/4/21 | 2/10/22 | 2/9/23 | 3/14/24 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 317.8 | 308.5 | 354.2 | 478.9 | 527 | 627.1 | 629.6 | 722 |
| EBITDA 1 | 44.22 | - | 37.23 | 62.37 | 49.79 | 68 | 70.87 | 80 |
| EBIT 1 | 35.11 | - | 19.46 | 43.01 | 32.23 | 51.1 | 53.37 | 63 |
| Operating Margin | 11.05% | - | 5.5% | 8.98% | 6.12% | 8.15% | 8.48% | 8.73% |
| Earnings before Tax (EBT) 1 | 35.37 | - | 17.18 | 38.14 | 25.83 | 41 | 48.9 | 60 |
| Net income 1 | 27.29 | 18.62 | 6.654 | 31.28 | 23.92 | 33.93 | 41.1 | 48 |
| Net margin | 8.59% | 6.03% | 1.88% | 6.53% | 4.54% | 5.41% | 6.53% | 6.65% |
| EPS 2 | 1,303 | - | 339.0 | 1,479 | 1,110 | 1,540 | 1,873 | 2,192 |
| Free Cash Flow 3 | 7,801 | - | - | 25,317 | - | 33,000 | 53,000 | 57,000 |
| FCF margin | 2,454.39% | - | - | 5,286.74% | - | 5,262.32% | 8,418.49% | 7,894.74% |
| FCF Conversion (EBITDA) | 17,640.33% | - | - | 40,589.36% | - | 48,529.41% | 74,788.33% | 71,250% |
| FCF Conversion (Net income) | 28,585.66% | - | - | 80,925.81% | - | 97,249.52% | 128,953.77% | 118,750% |
| Dividend per Share 2 | 240.4 | - | 200.0 | 200.0 | - | 300.0 | 333.3 | 300.0 |
| Announcement Date | 3/12/20 | 2/4/21 | 2/10/22 | 2/9/23 | 3/14/24 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 117 | 122.2 | 122.5 | 124.1 | 133 | 129 | 140.9 | 158.3 | 155.6 | 148.2 | 164.9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | 10.19 | 14.58 | 4.309 | 8.979 | 10.06 | 6.742 | 6.451 | 14.98 | 12.1 | 10.6 | 13.4 |
| Operating Margin | - | 8.71% | 11.93% | 3.52% | 7.24% | 7.56% | 5.23% | 4.58% | 9.46% | 7.78% | 7.15% | 8.13% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | 10.51 | 7.402 | 11.07 | - | - | - | 5.456 | 0.7494 | - | 7.2 | 6.4 | 9.9 |
| Net margin | - | 6.32% | 9.06% | - | - | - | 4.23% | 0.53% | - | 4.63% | 4.32% | 6% |
| EPS | 495.0 | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/16/22 | 8/16/22 | 11/11/22 | 2/9/23 | 5/15/23 | 8/11/23 | 11/14/23 | 3/14/24 | 5/16/24 | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 31.2 | - | - | 72.7 | - | 42.7 | 18.7 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 0.7056 x | - | - | 1.165 x | - | 0.6279 x | 0.2639 x | - |
| Free Cash Flow 2 | 7,801 | - | - | 25,317 | - | 33,000 | 53,000 | 57,000 |
| ROE (net income / shareholders' equity) | 14.1% | - | 3.09% | 12.9% | - | 11.8% | 13% | 13.8% |
| ROA (Net income/ Total Assets) | 9.05% | - | 1.83% | 7.08% | - | 6.5% | 7.37% | 7.9% |
| Assets 1 | 301.7 | - | 364 | 441.6 | - | 522.1 | 557.9 | 607.6 |
| Book Value Per Share 3 | 9,637 | - | 10,645 | 11,967 | - | 12,532 | 14,054 | 16,798 |
| Cash Flow per Share 3 | 1,949 | - | 1,088 | 1,523 | - | 1,467 | 2,403 | 2,587 |
| Capex 1 | 33 | - | 4.1 | 8.01 | - | 15 | 13.3 | 15 |
| Capex / Sales | 10.39% | - | 1.16% | 1.67% | - | 2.39% | 2.11% | 2.08% |
| Announcement Date | 3/12/20 | 2/4/21 | 2/10/22 | 2/9/23 | 3/14/24 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
14,810
KRW
Average target price
21,000
KRW
Spread / Average Target
+41.80%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -5.43% | 232M | |
| +36.83% | 723B | |
| +32.22% | 598B | |
| -2.28% | 364B | |
| +20.22% | 331B | |
| +3.54% | 288B | |
| +16.36% | 244B | |
| +9.87% | 210B | |
| -5.40% | 208B | |
| +8.92% | 169B |
- Stock Market
- Equities
- A003220 Stock
- Financials Daewon Pharmaceutical Co., Ltd.
